Effect of glibenclamide on antinociceptive effects of antidepressants of different classes

Clinics

Volumn 66, Issue 2, 2011, Pages 321-325

  Hajhashemi, Valiollah ^a   Amin, Bahareh ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antidepressants; Antinociceptive; ATP dependent K+ channels

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; FLUVOXAMINE; GLIBENCLAMIDE; MAPROTILINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT;

ANALYSIS OF VARIANCE; ANIMAL; ANIMAL MODEL; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG INTERACTION; MALE; MOUSE; PAIN; PAIN ASSESSMENT; RANDOMIZATION;

AMITRIPTYLINE; ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; DRUG INTERACTIONS; FLUVOXAMINE; GLYBURIDE; MALE; MAPROTILINE; MICE; MODELS, ANIMAL; PAIN; PAIN MEASUREMENT; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; RANDOM ALLOCATION;

EID: 79955488137     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000200023     Document Type: Article

References (32)

1. D'Mello R, Dickenson AH. Spinal cord mechanisms of pain. Br J Anaesth. 2008;101:8-16.
2. Chong MS, Brandner B. Neuropathic agents and pain. New strategies. Biomed Pharmacother. 2006;60:318-322.
3. Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol Clin Exp. 2004;19:15-19.
4. Richeimer SH, Bajwa ZH, Kahraman SS, Ransil BJ, Warfield CA. Utilisation patterns of tricyclic antidepressants in a multidisciplinary pain clinic: a survey. Clin J Pain. 1997;13:324-329.
5. Acton J, Mckenna JE, Melzack R. Amitriptyline produces analgesia in the formalin pain test. Exp Neurol. 1992;117:94-96.
6. Mico JA, Ardid D, Berrocoso E, Eschalier A. Antidepressants and pain. Trends Pharmacol Sci. 2006;27:348-354.
7. Yoshimura M, Furue H. Mechanisms for the anti-nociceptive actions of the descending noradrenergic and serotonergic systems in the spinal cord. J Pharmacol Sci. 2006;101:107-117.
8. Sawynok J. Adenosine receptor activation and nociception. Eur J Pharmacol. 1998;347:1-11.
9. Pareek SS, Chopde CT, Thahur Desai PA. Adenosine enhances analgesic effect of tricyclic antidepressants. Indian J Pharmacol. 1994;26:159-161.
10. Pancrazio JJ, Kamatchi GL, Roscoe AK, Lynch CIII. Inhibition of neuronal Na+ channels by antidepressant drugs. J Pharmacol Exp. 1998;284:208-214.
11. Deak F, Lasztoczi B, Pacher P, Petheö GL, Kecskemeti V, Spät A. Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells. Neuropharmacology. 2000;39:1029-1036.
12. Ni YG, Miledi R. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc Natl Acad Sci USA. 1997;94:2036-2049.
13. Fan P. Effects of antidepressants on the inward current mediated by 5-HT3 receptors in rat nodose ganglion neuron. Br J Pharmacol. 1994;112: 741-744.
14. Maggi L, Palma E, Miledi R, Eusebi F. Effects of fluoxetine on wild and mutant neuronal α7 nicotinic receptors. Mol Psychiatry. 1998;3:350-355.
15. Galeotti N, Ghelardini C, Bartolini A. Involvement of potassium channels in amitriptyline and clomipramine analgesia. Neuropharmacology. 2001;40:75-84.
16. DeFelipe MC, De Ceballos ML, Gil C, Fuentes JA. Chronic antidepressant treatment increases enkephalin levels in nucleus accumbens and striatum of the rat. Eur J Pharmacol. 1985;112:119-122.
17. Gray AM, Spencer PSJ, Sewell RDE. The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. Br J Pharmacol. 1998;124:669-674.
18. Hwang J, Zheng LT, Ock J, Lee MG, Kim SH, Lee HW. et al. Inhibition of glial inflammatory activation and neurotoxicity by tricyclic antidepressants. Neuropharmacology. 2008;55:826-834.
19. Mao QX, Yang TD. Amitriptyline upregulates EAAT1 and EAAT2 in neuropathic pain rats. Brain Res Bull. 2010;81:424-427.
20. Sernagor E, Kuhn D, Vyklicky Jr L, Mayer ML. Open channel block of NMDA receptor responses evoked by tricyclic antidepressants. Neuron. 1989;2:1221-1227.
21. Ocana MA, Cendan CM, Cobos EJ, Entrena JM, Baeyens JM. Potassium channels and pain: present realities and future opportunities. Eur J Pharmacol. 2004;500:203-219.
22. Welch SP, Dunlow LD. Antinociceptive activity of intrathecally administered potassium channel openers and opioid agonists, a common mechanism of action? J Pharmacol Exp Ther. 1993;267:390-399.
23. Galeotti N, Ghelardini C, Bartolini A. The role of potassium channels in antihistamine analgesia. Neuropharmacology. 1990;38:1893-1901.
24. + channel. Eur J Pharmacol. 1997;330:15-25.
25. Dubuisson D, Dennis SG. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. 1977;4:161-174.
26. Woolf CJ. Moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med. 2004;140:441-451.
27. Casis O, Gallego M, Sánchez-Chapula JA. Imipramine, mianserine and maprotiline block delayed rectifier potassium current in ventricular myocytes. Pharmacol Res. 2002;45:141-146.
28. Bobker DH, Williams JT. Ion conductance affected by 5-HT receptor subtypes in mammalian neurones. Trends Neurosci. 1990;13: 169-173.
29. Bardin L, Tarayre JP, Malfetes N, Koek W, Colpaert FC. Profound, nonopioid analgesia produced by the high-efficacy 5-HT(1A) agonist F 13640 in the formalin model of tonic nociceptive pain. Pharmacology. 2003;67:182-194.
30. Colpaert FC. 5-HT1A receptor activation: new molecular and neuroadaptive mechanisms of pain relief. Curr Opin in Investig Drugs. 2006;7:40-47.
31. Bonnefont J, Chapuy E, Clottes E, Alloui A, Eschalier A. Spinal 5-HT1A receptors differentially influence nociceptive processing according to the nature of the noxious stimulus in rats: effect of WAY-100635 on the antinociceptive activities of paracetamol, venlafaxine and 5-HT. Pain. 2005;114:482-490.
32. + channel blockers and openers on antinociception induced by agonists of 5-HT1A receptors. Eur J Pharmacol. 1996;295:181-188.